1. Home
  2. INTS vs RDI Comparison

INTS vs RDI Comparison

Compare INTS & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$0.40

Market Cap

24.0M

Sector

Health Care

ML Signal

HOLD

RDI

Reading International Inc

HOLD

Current Price

$1.07

Market Cap

23.6M

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTS
RDI
Founded
2012
1937
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Movies/Entertainment
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
24.0M
23.6M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
INTS
RDI
Price
$0.40
$1.07
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$4.33
N/A
AVG Volume (30 Days)
2.5M
505.1K
Earning Date
11-06-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$211,292,000.00
Revenue This Year
N/A
$1.06
Revenue Next Year
N/A
$10.97
P/E Ratio
N/A
N/A
Revenue Growth
N/A
7.11
52 Week Low
$0.19
$1.00
52 Week High
$3.17
$1.87

Technical Indicators

Market Signals
Indicator
INTS
RDI
Relative Strength Index (RSI) 46.75 37.93
Support Level $0.39 $1.01
Resistance Level $0.42 $1.10
Average True Range (ATR) 0.03 0.05
MACD -0.00 0.01
Stochastic Oscillator 42.15 41.52

Price Performance

Historical Comparison
INTS
RDI

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

Share on Social Networks: